The strategy charges fees in line with its similarly distributed peers, priced within the middle quintile.
Fidelity Advisor Biotechnology A FBTAX
- NAV / 1-Day Return 27.93 / −1.06 %
- Total Assets 1.8 Bil
-
Adj. Expense Ratio
- Expense Ratio 1.010%
- Distribution Fee Level Low
- Share Class Type Front Load
- Category Health
- Investment Style Mid Blend
- Min. Initial Investment —
- Status Open
- TTM Yield 1.02%
- Turnover 78%
USD | NAV as of Apr 25, 2024 | 1-Day Return as of Apr 25, 2024, 10:10 PM GMT+0
Morningstar’s Analysis FBTAX
Will FBTAX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 62.7
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
AbbVie Inc | 24.05 | 427.7 Mil | Healthcare |
Amgen Inc | 9.25 | 164.6 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 7.98 | 141.8 Mil | Healthcare |
Ascendis Pharma A/S ADR | 3.95 | 70.2 Mil | Healthcare |
Alnylam Pharmaceuticals Inc | 3.41 | 60.6 Mil | Healthcare |
Cytokinetics Inc | 3.27 | 58.2 Mil | Healthcare |
Viking Therapeutics Inc | 3.07 | 54.6 Mil | Healthcare |
Gilead Sciences Inc | 3.01 | 53.6 Mil | Healthcare |
Vaxcyte Inc Ordinary Shares | 2.49 | 44.2 Mil | Healthcare |
argenx SE ADR | 2.24 | 39.9 Mil | Healthcare |